In this issue:
Cetuximab added to FOLFIRI beneficial
Cetuximab + irinotecan improves HRQoL
MOSAIC trial confirms FOLFOX4 benefit
Advanced colorectal cancer treatment options
Meeting the 12 LN benchmark
Diet may influence cancer recurrence
Communicating about adjuvant chemotherapy
Biological markers for cetuximab sensitivity
PET changes cancer management
XELOX non-inferior to FOLFOX4
Download PDF